WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 2749

Summary of SB 2749: Relating to Health

Bill Overview

Bill Number: SB 2749
Title: Relating to Health
Introduced On: January 19, 2024
Current Status: Referred to PSM/HHS, JDC
Classification: Bill
Subject Areas: Controlled Substance, Emergency Scheduling, Schedule III, Test Strip, Xylazine

Purpose and Intent

The primary purpose of SB 2749 is to address public health concerns related to the increasing prevalence of xylazine, a non-opioid sedative that has been linked to a rise in overdose deaths when used in combination with opioids. The bill aims to enhance the state's ability to respond to this emerging health crisis by implementing emergency scheduling measures for xylazine as a controlled substance.

Key Provisions

  • Emergency Scheduling of Xylazine: The bill proposes to classify xylazine as a Schedule III controlled substance. This classification will allow for stricter regulation of the substance, including its distribution and use.

  • Test Strips for Detection: The bill includes provisions for the distribution and use of test strips that can detect the presence of xylazine in substances. This is intended to provide individuals with tools to identify the presence of xylazine in drugs, thereby reducing the risk of unintentional overdose.

  • Public Health Initiatives: The bill may also allocate resources for public health campaigns aimed at educating the community about the dangers of xylazine and promoting harm reduction strategies.

Affected Parties

  • Individuals at Risk: The bill primarily affects individuals who may be exposed to xylazine through drug use, particularly those using opioids.

  • Healthcare Providers: Medical professionals and emergency responders will need to be aware of the new regulations and the implications of xylazine use in overdose situations.

  • Law Enforcement: The classification of xylazine as a controlled substance will impact law enforcement agencies in terms of regulation and enforcement.

Legislative Timeline

  • January 19, 2024: SB 2749 was introduced in the legislature.
  • January 22, 2024: The bill passed its first reading, indicating initial approval to move forward in the legislative process.
  • January 24, 2024: The bill was referred to the committees on Public Safety, Intergovernmental, and Military Affairs (PSM), Health and Human Services (HHS), and Judiciary and Government (JDC) for further consideration.

Related Legislation

  • HB 2086: This bill serves as a companion to SB 2749, suggesting parallel legislative efforts to address the issues surrounding xylazine and its impact on public health.

Conclusion

SB 2749 represents a proactive legislative effort to combat the rising health threats posed by xylazine. By classifying it as a controlled substance and promoting harm reduction strategies, the bill seeks to protect vulnerable populations and enhance public health responses to drug-related emergencies.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.